Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.
Trial locations(31 sites)
India
Local Institution - 0014, Hyderabad, Andhra Pradesh Local Institution - 0011, Ahmedabad, Gujarat Local Institution - 0006, Surat, Gujarat Local Institution - 0020, Gurgaon, Haryana Medanta Heart Institute, Gurgaon, Haryana Local Institution - 0004, Belagavi, Karnataka Local Institution - 0008, Mangalore, Karnataka Local Institution - 0002, Ernākulam, Kerala Local Institution - 0001, Kottayam, Kerala Local Institution - 0012, Aurangabad, Maharashtra Local Institution - 0025, Mumbai, Maharashtra Local Institution - 0025, Mumbai, Maharashtra Local Institution - 0013, Nagpur, Maharashtra Local Institution - 0019, Nagpur, Maharashtra Local Institution - 0024, Nagpur, Maharashtra Local Institution - 0024, Nagpur, Maharashtra Local Institution - 0010, Pune, Maharashtra Local Institution - 0021, New Delhi, National Capital Territory of Delhi Local Institution - 0021, New Delhi, National Capital Territory of Delhi Local Institution - 0005, New Delhi, National Capital Territory of Delhi Local Institution - 0016, Bhubaneswar, Odisha Local Institution - 0018, Cuttack, Odisha Local Institution - 0015, Ludhiana, Punjab Local Institution - 0007, Bikaner, Rajasthan Local Institution - 0003, Chennai, Tamil Nadu Local Institution - 0022, Aligarh, Uttar Pradesh Local Institution - 0022, Aligarh, Uttar Pradesh Laxmipat Singhania Institute of Cardiology, Kanpur, Uttar Pradesh Local Institution - 0023, Kanpur, Uttar Pradesh Local Institution - 0017, Kolkata, West Bengal Local Institution - 0009, New Delhi